How to Make an Emerona Vaccine in a Vacine Plant in India

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

There seems to be a bit of a push pull between the current big vaccine designers, i suppose, patent holders and the manufacturers about how practical it is to actually produce an emerona vaccine in india. Even if that were to happen, it would take a long time for other companies to sort of like reverse engineer how to make these vaccines. And so if our goal, if our shared world goal was getting people vaccinated as soon as possible, that's not a fast approach.

Less than 1% of those in low income countries are fully vaccinated, and that number only rises to 10% in low-middle income countries. Meanwhile more than half of the population in wealthier countries have received a double dose with several now rolling out third dosess.

In this episode of Coronapod we look at the role of pharmaceutical manufacturers. Drug companies are facing increased pressure to partner with manufacturing firms in the global south but most are reluctant to relinquish control. We ask what needs to change to help address the global disparity in vaccine access.

News: The fight to manufacture COVID vaccines in lower-income countries

Hosted on Acast. See acast.com/privacy for more information.